165 related articles for article (PubMed ID: 38644240)
1. [Organ preservation in locally advanced colorectal cancer with microsatellite instability-high after immunotherapy].
Hong ZG; Xiao BY; Ding PR
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):353-358. PubMed ID: 38644240
[TBL] [Abstract][Full Text] [Related]
2. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
Front Immunol; 2022; 13():913483. PubMed ID: 35958603
[TBL] [Abstract][Full Text] [Related]
4. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.
Xiao BY; Zhang X; Cao TY; Li DD; Jiang W; Kong LH; Tang JH; Han K; Zhang CZ; Mei WJ; Xiao J; Pan ZZ; Li YF; Zhang XS; Ding PR
J Natl Compr Canc Netw; 2023 Jan; 21(1):60-66.e5. PubMed ID: 36630898
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti-PD-1-Based Immunotherapy as Curative-Intent Treatment.
Yu JH; Liao LE; Xiao BY; Zhang X; Wu AW; Cheng Y; Tang JH; Jiang W; Kong LH; Han K; Mei WJ; Hong ZG; Yang WJ; Li DD; Pan ZZ; Li YF; Zhang XS; Ding PR
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38498975
[TBL] [Abstract][Full Text] [Related]
8. Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study.
Yang R; Wu T; Yu J; Cai X; Li G; Li X; Huang W; Zhang Y; Wang Y; Yang X; Ren Y; Hu R; Feng Q; Ding P; Zhang X; Li Y
Front Immunol; 2023; 14():1182299. PubMed ID: 37441082
[TBL] [Abstract][Full Text] [Related]
9. Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors.
Xie Y; Lin J; Zhang N; Wang X; Wang P; Peng S; Li J; Wu Y; Huang Y; Zhuang Z; Shen D; Zhu M; Liu X; Liu G; Meng X; Huang M; Yu H; Luo Y
J Natl Compr Canc Netw; 2023 Feb; 21(2):133-142.e3. PubMed ID: 36791752
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study.
Han K; Tang JH; Liao LE; Jiang W; Sui QQ; Xiao BY; Li WR; Hong ZG; Li Y; Kong LH; Li DD; Zhang XS; Pan ZZ; Steele SR; Ding PR
Dis Colon Rectum; 2023 Oct; 66(10):e996-e1005. PubMed ID: 35485833
[TBL] [Abstract][Full Text] [Related]
11. [Neoadjuvant immunotherapy for colorectal cancer].
Pei JP; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):58-67. PubMed ID: 36650001
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series.
Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer.
Liu DX; Li DD; He W; Ke CF; Jiang W; Tang JH; Kong LH; Li Y; Sui QQ; Xiao BY; Li WR; Hong ZG; Xu RH; Pan ZZ; Zhang XS; Ding PR
Oncoimmunology; 2020; 9(1):1711650. PubMed ID: 32042474
[No Abstract] [Full Text] [Related]
15. Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study.
Wang QX; Xiao BY; Cheng Y; Wu AW; Zhang T; Wang H; Zhang X; Huang WX; Tang JH; Jiang W; Steele SR; Krishnamurthi S; Li Y; Cai J; Kong LH; Li DD; Pan ZZ; Zhang XS; Ding PR
Eur J Cancer; 2022 Oct; 174():176-184. PubMed ID: 36030556
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer: The future new standard approach?
Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Díaz-Pérez D; Mateos-Dominguez M; Galindo-Jara P
Eur J Surg Oncol; 2023 Feb; 49(2):323-328. PubMed ID: 36400657
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies.
Li YJ; Liu XZ; Yao YF; Chen N; Li ZW; Zhang XY; Lin XF; Wu AW
World J Gastrointest Surg; 2023 Feb; 15(2):222-233. PubMed ID: 36896306
[TBL] [Abstract][Full Text] [Related]
19. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy for microsatellite-instability-high advanced colorectal cancer].
Ding PR
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):199-204. PubMed ID: 35340168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]